• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience
Conclusion: It is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.
Source: In Vivo - February 25, 2019 Category: Research Authors: SCHIZAS, D., THEOCHARI, N. A., THEOCHARI, C. A., KOKKINIDIS, D. G., DOMI, V., MPAILI, E., JONNALAGADDA, A. K., KAPELOUZOU, A., BAKOPOULOS, A., LIAKAKOS, T. Tags: Clinical Studies Source Type: research

Chemoprevention of Barrett ’s Esophagus and Esophageal Adenocarcinoma
AbstractBarrett ’s esophagus is common in Western countries, but progression to esophageal adenocarcinoma is uncommon. Chemoprevention therefore needs to consider whether benefits outweigh risks given an otherwise healthy population. This will depend on the particular population at risk and the relative safety of a potential preventive agent. Most evidence regarding the potential benefit of chemoprevention of Barrett’s esophagus and prevention of progression to esophageal adenocarcinoma is based on observational studies such as case–control and cohort studies. Given the potential benefits and relatively low risks, pa...
Source: Digestive Diseases and Sciences - June 12, 2018 Category: Gastroenterology Source Type: research

Portable disposable ultrathin endoscopy tested through percutaneous endoscopic gastrostomy
Conclusions: Our study shows that portable DUE in facilities without endoscopy equipment may be clinically feasible.
Source: Medicine - November 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Daily low-dose aspirin may help combat cancer
Conclusion The systematic review looked at 47 studies and attempted to combine the results, looking for evidence of a beneficial effect of low-dose aspirin on risk of death in people already diagnosed with cancer. The few RCTs identified – the best-quality evidence – did not provide conclusive evidence that aspirin improves survival rates. The rest of the studies were observational in nature, so cannot prove that aspirin reduces the risk of death from cancer. The only significant results were for a 24% reduction in risk of death from colon cancer, and a possible 11% reduced risk of death from prostate cancer. However,...
Source: NHS News Feed - April 22, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Daily aspirin 'reduces cancer risk', study finds
Conclusion While the findings on aspirin and cancer show promise, it is not clear that the results are reliable from the methods reportedly used to compile this review. This is because it included studies of varying design and quality, with much of the evidence coming from observational studies, which, while useful, cannot be totally relied on to test the effectiveness of healthcare interventions. It's not clear how the studies included in the review were chosen and whether others on the same topic were excluded. It is also not clear whether or not this was a systematic review, where studies are rigorously appraised for ...
Source: NHS News Feed - August 6, 2014 Category: Consumer Health News Tags: Cancer Medication Source Type: news